| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$50,235,035 |
|
|
|
Indirect Value
|
$10,282,624 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,517,659 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
853 |
52,744 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-05 |
4 |
S |
$606.78 |
$14,569,134 |
D/D |
(23,782) |
52,795 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
53,100 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-22 |
4 |
S |
$840.53 |
$9,810,082 |
D/D |
(11,665) |
53,100 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-11 |
4 |
D |
$664.34 |
$500,248 |
D/D |
(753) |
53,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-03-30 |
4 |
OE |
$13.00 |
$99,996 |
D/D |
7,692 |
58,042 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
OE |
$30.63 |
$818,924 |
D/D |
26,736 |
58,709 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-15 |
4 |
S |
$107.79 |
$2,273,036 |
D/D |
(21,082) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
• – – |
2012-06-19 |
4 |
AS |
$115.60 |
$4,514,593 |
D/D |
(38,911) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-29 |
4 |
S |
$144.92 |
$2,460,647 |
D/D |
(16,884) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-21 |
4 |
S |
$173.80 |
$4,245,442 |
D/D |
(24,357) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-02 |
4 |
D |
$956.65 |
$21,728,391 |
D/D |
(22,713) |
60,056 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
D |
$567.63 |
$32,865,209 |
D/D |
(57,899) |
64,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
D |
$833.39 |
$31,948,006 |
D/D |
(38,335) |
64,765 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-10 |
4 |
D |
$268.40 |
$8,696,160 |
D/D |
(32,400) |
72,026 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-28 |
4 |
D |
$145.70 |
$3,368,001 |
D/D |
(23,116) |
76,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
D |
$613.00 |
$43,656,634 |
D/D |
(71,218) |
76,577 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
OE |
$21.25 |
$2,828,500 |
D/D |
100,000 |
78,377 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-14 |
4 |
S |
$107.83 |
$3,436,651 |
D/D |
(31,202) |
80,203 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-02 |
4 |
OE |
$399.66 |
$12,289,545 |
D/D |
30,750 |
82,769 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-20 |
4 |
D |
$167.17 |
$5,039,005 |
D/D |
(30,143) |
83,478 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-06 |
4 |
D |
$65.76 |
$3,226,054 |
D/D |
(49,058) |
84,110 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-04 |
4 |
D |
$45.53 |
$2,649,527 |
D/D |
(58,193) |
84,465 |
0 |
- |
|
140 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
